Galantamine, an acetylcholinesterase inhibitor (AChEI), has demonstrated promising results in preventing the induction of TNBS-65 and DSS-induced colitis,66 an effect mediated by central muscarinic (mAChR) activation of the CAP65 and dependent on the vagus nerve and α7nAChR. The gene discussed is CHRNA7; the disease is colitis.